

General information about company	
Scrip code*	524404
NSE Symbol*	MARKSANS
MSEI Symbol*	NOTLISTED
ISIN*	INE750C01026
Name of company	MARKSANS PHARMA LIMITED
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-04-2025
Date of end of financial year	31-03-2026
Date of board meeting when results were approved	13-11-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	23-10-2025
Description of presentation currency	INR
Level of rounding	Millions
Reporting Type	Quarterly
Reporting Quarter	Second quarter
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited for the quarter ended	Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Unaudited
Segment Reporting	Single segment
Description of single segment	Pharmaceutical Formulation
Start date and time of board meeting	13-11-2025 17:40
End date and time of board meeting	13-11-2025 18:40
Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?	
(b) If answer to above question is No, please explain the reason for not complying.	
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?	Yes
Latest Date on which RPT policy is updated	11-02-2025
Indicate Company website link for updated RPT policy of the Company	https://www.marksanspharma.com/pdf/Policy-on-materiality-of-related-party-transactions-and-on-dealing-with-related-party-transactions.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	Yes
No. of times funds raised during the quarter	1
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	No The Company has no outstanding loans and debt securities.

Financial Results - Ind-AS				
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)	
Date of start of reporting period		01-07-2025	01-04-2025	
Date of end of reporting period		30-09-2025	30-09-2025	
Whether results are audited or unaudited		Unaudited	Unaudited	
Nature of report standalone or consolidated		Standalone	Standalone	
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.			
1	Income			
	Revenue from operations	3204.41	6401.75	
	Other income	581.89	601.99	
	Total income	3786.3	7003.74	
2	Expenses			
(a)	Cost of materials consumed	1466.64	2919.41	
(b)	Purchases of stock-in-trade	209.86	437.84	
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-21.73	-54.64	
(d)	Employee benefit expense	284.56	563.6	
(e)	Finance costs	3.15	6.17	
(f)	Depreciation, depletion and amortisation expense	84.56	166.44	
(g)	Other Expenses			
1	Other Expenses	544.33	1114.25	
	Total other expenses	544.33	1114.25	
	Total expenses	2571.37	5153.07	
3	Total profit before exceptional items and tax			
		1214.93	1850.67	
4	Exceptional items	0	0	
5	Total profit before tax			
		1214.93	1850.67	
6	Tax expense			
7	Current tax	208.05	353.43	
8	Deferred tax	8.82	18.62	
9	Total tax expenses			
		216.87	372.05	
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0	
11	Net Profit Loss for the period from continuing operations			
		998.06	1478.62	
12	Profit (loss) from discontinued operations before tax	0	0	
13	Tax expense of discontinued operations	0	0	
14	Net profit (loss) from discontinued operation after tax			
		0	0	
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0	
16	Total profit (loss) for period			
		998.06	1478.62	
17	Other comprehensive income net of taxes	-0.74	-1.5	
18	Total Comprehensive Income for the period			
		997.32	1477.12	
19	Total profit or loss, attributable to			
	Profit or loss, attributable to owners of parent			
	Total profit or loss, attributable to non-controlling interests			
20	Total Comprehensive income for the period attributable to			
	Comprehensive income for the period attributable to owners of parent			
	Total comprehensive income for the period attributable to owners of parent non-controlling interests			
21	Details of equity share capital			
	Paid-up equity share capital	453.16	453.16	
	Face value of equity share capital	1	1	
22	Reserves excluding revaluation reserve			
23	Earnings per share			
i	Earnings per equity share for continuing operations			
	Basic earnings (loss) per share from continuing operations	2.2	3.26	
	Diluted earnings (loss) per share from continuing operations	2.2	3.26	
ii	Earnings per equity share for discontinued operations			
	Basic earnings (loss) per share from discontinued operations	0	0	
	Diluted earnings (loss) per share from discontinued operations	0	0	
iii	Earnings per equity share (for continuing and discontinued operations)			
	Basic earnings (loss) per share from continuing and discontinued operations	2.2	3.26	
	Diluted earnings (loss) per share from continuing and discontinued operations	2.2	3.26	
24	Debt equity ratio			Textual Information(1)
25	Debt service coverage ratio			Textual Information(2)
26	Interest service coverage ratio			Textual Information(

			3)
27	Disclosure of notes on financial results	Textual Information(4)	

Text Block

Textual Information(4)

NOTES TO STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30 SEPTEMBER 2025.

1. The standalone unaudited financial results for the quarter and half year ended 30 September 2025 were reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 13 November 2025. The Statutory Auditors of the Company have carried out limited review on the above results in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ('the Regulation'), as amended and expressed an unmodified conclusion.

2. The standalone unaudited financial results of the Company have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognised accounting principles generally accepted in India and in terms of the Regulation.

3. The Company operates in one reportable business segment namely 'Pharmaceuticals' as per Ind AS 108 on 'Operating Segments'.

4. Other income (net) includes the following net foreign exchange differences including forward contracts:

Description	Quarter ended 30-Sep-25	Half year ended 30-Jun-25	Year ended 30-Sep-24	Year ended 30-Sep-25	Year ended 31-Mar-25
-------------	-------------------------	---------------------------	----------------------	----------------------	----------------------

Net gain / (loss)	175.10	(37.73)	(122.49)	137.37	(96.38)	194.80
-------------------	--------	---------	----------	--------	---------	--------

5. During half year ended 30 September 2025, the Board of Directors and Shareholders of the Company have approved the Marksans Employees Stock Option Scheme 2024 ("Scheme") for the employees of the Company and its subsidiary companies comprising of equity shares of the Company, not exceeding 2,300,000 equity share of face value of Re 1/- each. Under the said Scheme, the Company has granted 400,000 equity stock options of face value of Re 1/- each on 24 September 2025 to the eligible employees of the Company and its Subsidiary Companies.

Statement of Asset and Liabilities	
Particulars	Half Year ended (dd-mm-yyyy)
Date of start of reporting period	01-04-2025
Date of end of reporting period	30-09-2025
Whether results are audited or unaudited	Unaudited
Nature of report standalone or consolidated	Standalone
Assets	
1 Non-current assets	
Property, plant and equipment	3954.18
Capital work-in-progress	
Investment property	
Goodwill	0
Other intangible assets	21.14
Intangible assets under development	
Biological assets other than bearer plants	
Investments accounted for using equity method	
Non-current financial assets	
Non-current investments	2658.07
Trade receivables, non-current	
Loans, non-current	0
Other non-current financial assets	10.61
Total non-current financial assets	2668.68
Deferred tax assets (net)	
Other non-current assets	234.64
Total non-current assets	6878.64
2 Current assets	
Inventories	2012.21
Current financial asset	
Current investments	7.83
Trade receivables, current	6209.78
Cash and cash equivalents	817.31
Bank balance other than cash and cash equivalents	1819.97
Loans, current	0
Other current financial assets	18.85
Total current financial assets	8873.74
Current tax assets (net)	
Other current assets	403.87
Total current assets	11289.82
3 Non-current assets classified as held for sale	
4 Regulatory deferral account debit balances and related deferred tax Assets	
Total assets	18168.46
Total current assets	11289.82
3 Non-current assets classified as held for sale	
4 Regulatory deferral account debit balances and related deferred tax Assets	
Total assets	18168.46
Equity and liabilities	
1 Equity	
Equity attributable to owners of parent	
Equity share capital	453.16
Other equity	14497.53
Total equity attributable to owners of parent	14950.69
Non controlling interest	
Total equity	14950.69
2 Liabilities	
Non-current liabilities	
Non-current financial liabilities	
Borrowings, non-current	0
Trade Payables, non-current	
(A) Total outstanding dues of micro enterprises and small enterprises	
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	
Total Trade payable	
Other non-current financial liabilities	84.3
Total non-current financial liabilities	84.3
Provisions, non-current	60.97
Deferred tax liabilities (net)	139.64
Deferred government grants, Non-current	
Other non-current liabilities	
Total non-current liabilities	284.91
Current liabilities	
Current financial liabilities	
Borrowings, current	0
Trade Payables, current	
(A) Total outstanding dues of micro enterprises and small enterprises	21.01
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	1464.47
Total Trade payable	1485.48

	Other current financial liabilities	313.26
	Total current financial liabilities	1798.74
	Other current liabilities	971.02
	Provisions, current	15.32
	Current tax liabilities (Net)	147.78
	Deferred government grants, Current	
	Total current liabilities	2932.86
3	Liabilities directly associated with assets in disposal group classified as held for sale	
4	Regulatory deferral account credit balances and related deferred tax liability	
	Total liabilities	3217.77
	Total equity and liabilities	18168.46
	Disclosure of notes on assets and liabilities	Textual Information(1)

Other Comprehensive Income			
	Date of start of reporting period	01-07-2025	01-04-2025
	Date of end of reporting period	30-09-2025	30-09-2025
	Whether results are audited or unaudited	Unaudited	Unaudited
	Nature of report standalone or consolidated	Standalone	Standalone
	Other comprehensive income [Abstract]		
1	Amount of items that will not be reclassified to profit and loss		
1	Remeasurements of the net defined benefit liabilities/assets	-1.00	-2.01
	Total Amount of items that will not be reclassified to profit and loss	-1.00	-2.01
2	Income tax relating to items that will not be reclassified to profit or loss	-0.26	-0.51
3	Amount of items that will be reclassified to profit and loss		
1	Remeasurements of the net defined benefit liabilities/assets	0.00	0.00
	Total Amount of items that will be reclassified to profit and loss	0.00	0.00
4	Income tax relating to items that will be reclassified to profit or loss	0.00	0.00
5	Total Other comprehensive income	-0.74	-1.50

Cash flow statement, indirect		
Particulars		Half Year ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2025
Date of end of reporting period		30-09-2025
Whether results are audited or unaudited		Unaudited
Nature of report standalone or consolidated		Standalone
Part I	Blue color marked fields are non-mandatory.	
1	Statement of cash flows	
	Cash flows from used in operating activities	
	Profit before tax	1850.67
2	Adjustments for reconcile profit (loss)	
	Adjustments for finance costs	6.17
	Adjustments for decrease (increase) in inventories	39.89
	Adjustments for decrease (increase) in trade receivables, current	-646.98
	Adjustments for decrease (increase) in trade receivables, non-current	0
	Adjustments for decrease (increase) in other current assets	153.21
	Adjustments for decrease (increase) in other non-current assets	3.69
	Adjustments for other financial assets, non-current	-0.34
	Adjustments for other financial assets, current	-0.06
	Adjustments for other bank balances	0
	Adjustments for increase (decrease) in trade payables, current	-551.2
	Adjustments for increase (decrease) in trade payables, non-current	0
	Adjustments for increase (decrease) in other current liabilities	-90.34
	Adjustments for increase (decrease) in other non-current liabilities	0
	Adjustments for depreciation and amortisation expense	166.44
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	0
	Adjustments for provisions, current	-1.16
	Adjustments for provisions, non-current	3.27
	Adjustments for other financial liabilities, current	14.22
	Adjustments for other financial liabilities, non-current	0
	Adjustments for unrealised foreign exchange losses gains	-160.07
	Adjustments for dividend income	386.16
	Adjustments for interest income	76.85
	Adjustments for share-based payments	0
	Adjustments for fair value losses (gains)	76.39
	Adjustments for undistributed profits of associates	0
	Other adjustments for which cash effects are investing or financing cash flow	-0.47
	Other adjustments to reconcile profit (loss)	0
	Other adjustments for non-cash items	95.45
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0
	Total adjustments for reconcile profit (loss)	-1354.9
	Net cash flows from (used in) operations	495.77
	Dividends received	0
	Interest paid	0
	Interest received	0
	Income taxes paid (refund)	310.91
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) operating activities	184.86
3	Cash flows from used in investing activities	
	Cash flows from losing control of subsidiaries or other businesses	0
	Cash flows used in obtaining control of subsidiaries or other businesses	0
	Other cash receipts from sales of equity or debt instruments of other entities	0
	Other cash payments to acquire equity or debt instruments of other entities	0
	Other cash receipts from sales of interests in joint ventures	0
	Other cash payments to acquire interests in joint ventures	0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0
	Proceeds from sales of property, plant and equipment	2.62
	Purchase of property, plant and equipment	328.08
	Proceeds from sales of investment property	0
	Purchase of investment property	0
	Proceeds from sales of intangible assets	0
	Purchase of intangible assets	0
	Proceeds from sales of intangible assets under development	0
	Purchase of intangible assets under development	0
	Proceeds from sales of goodwill	0
	Purchase of goodwill	0
	Proceeds from biological assets other than bearer plants	0
	Purchase of biological assets other than bearer plants	0
	Proceeds from government grants	0
	Proceeds from sales of other long-term assets	0
	Purchase of other long-term assets	0
	Cash advances and loans made to other parties	0

	Cash receipts from repayment of advances and loans made to other parties	0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts	0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0
	Dividends received	386.16
	Interest received	80.97
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	264.75
	Net cash flows from (used in) investing activities	406.42
4	Cash flows from used in financing activities	
	Proceeds from changes in ownership interests in subsidiaries	0
	Payments from changes in ownership interests in subsidiaries	0
	Proceeds from issuing shares	0
	Proceeds from issuing other equity instruments	0
	Payments to acquire or redeem entity's shares	0
	Payments of other equity instruments	0
	Proceeds from exercise of stock options	0
	Proceeds from issuing debentures notes bonds etc	0
	Proceeds from borrowings	0
	Repayments of borrowings	0
	Payments of lease liabilities	14.09
	Dividends paid	362.53
	Interest paid	0
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) financing activities	-376.62
	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes	214.66
5	Effect of exchange rate changes on cash and cash equivalents	
	Effect of exchange rate changes on cash and cash equivalents	-0.03
	Net increase (decrease) in cash and cash equivalents	214.63
	Cash and cash equivalents cash flow statement at beginning of period	602.68
	Cash and cash equivalents cash flow statement at end of period	817.31

Format for Disclosure of Related Party Transactions (applicable only for

Sr. No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary						
1	Marksans Pharma Limited	AAACT3153G	Nova Pharmaceuticals Australasia Pty Ltd	ZZZZZ9999Z	Subsidiary	Sale of goods or services			0		
2	Marksans Pharma Limited	AAACT3153G	Nova Pharmaceuticals Australasia Pty Ltd	ZZZZZ9999Z	Subsidiary	Any other transaction	Receivables		0		
3	Marksans Pharma Limited	AAACT3153G	Bell Sons & Co. (Druggists) Ltd	ZZZZZ9999Z	Subsidiary	Sale of goods or services			0		
4	Marksans Pharma Limited	AAACT3153G	Bell Sons & Co. (Druggists) Ltd	ZZZZZ9999Z	Subsidiary	Advance			0		
5	Marksans Pharma Limited	AAACT3153G	Relonchem Limited	ZZZZZ9999Z	Subsidiary	Sale of goods or services			0		
6	Marksans Pharma Limited	AAACT3153G	Relonchem Limited	ZZZZZ9999Z	Subsidiary	Any other transaction	Reimbursement of Expenses		0		
7	Marksans Pharma Limited	AAACT3153G	Relonchem Limited	ZZZZZ9999Z	Subsidiary	Advance			0		
8	Marksans Pharma Limited	AAACT3153G	Relonchem Limited	ZZZZZ9999Z	Subsidiary	Purchase of goods or services			0		
9	Marksans Pharma Limited	AAACT3153G	Relonchem Limited	ZZZZZ9999Z	Subsidiary	Any other transaction	Payables		0		
10	Marksans Pharma Limited	AAACT3153G	Time Cap Laboratories Inc	ZZZZZ9999Z	Subsidiary	Sale of goods or services			0		
11	Marksans Pharma Limited	AAACT3153G	Time Cap Laboratories Inc	ZZZZZ9999Z	Subsidiary	Sale of fixed assets			0		
12	Marksans Pharma Limited	AAACT3153G	Time Cap Laboratories Inc	ZZZZZ9999Z	Subsidiary	Any other transaction	Receivables		0		
13	Marksans Pharma Limited	AAACT3153G	Time Cap Laboratories Inc	ZZZZZ9999Z	Subsidiary	Purchase of goods or services			0		
14	Marksans Pharma Limited	AAACT3153G	Time Cap Laboratories Inc	ZZZZZ9999Z	Subsidiary	Any other transaction	Payables		0		
15	Marksans Pharma Limited	AAACT3153G	Marksans Pharma UK Limited	ZZZZZ9999Z	Subsidiary	Dividend received			0		
16	Marksans Pharma Limited	AAACT3153G	Access Healthcare For Medical Products LLC	ZZZZZ9999Z	Subsidiary	Any other transaction	Receivables		0		
17	Marksans Pharma Limited	AAACT3153G	Mark Saldanha	AHAPS0915M	Managing Director	Remuneration			0		
18	Marksans Pharma Limited	AAACT3153G	Mark Saldanha	AHAPS0915M	Managing Director	Any other transaction	Rent Paid		0		
19	Marksans Pharma Limited	AAACT3153G	Sandra Saldanha	ALRPS8186P	Whole-time Director	Remuneration			0		
20	Marksans Pharma Limited	AAACT3153G	Vardhman Vikramaditya Jain	ACWPJ0702A	Whole-time Director	Remuneration			0		
21	Marksans Pharma Limited	AAACT3153G	Jitendra Sharma	AJCPS5121K	Chief Financial Officer	Remuneration			0		
22	Marksans Pharma Limited	AAACT3153G	Harshavardhan Panigrahi	AKTPP1644A	Company Secretary	Remuneration			0		
23	Marksans Pharma Limited	AAACT3153G	Abhinna Sundar Mohanty	AAAPM5371J	Independent Director	Any other transaction	Sitting Fees		0		
24	Marksans Pharma Limited	AAACT3153G	Digant Mahesh Parikh	AAFPP7379G	Independent Director	Any other transaction	Sitting Fees		0		
25	Marksans Pharma Limited	AAACT3153G	Shailaja Vardhan	AOZPS7018B	Independent Director	Any other transaction	Sitting Fees		0		
26	Marksans Pharma Limited	AAACT3153G	Srinivas Mishra	ADHPM0097M	Independent Director	Any other transaction	Sitting Fees		0		
27	Time Cap Laboratories Inc	ZZZZZ9999Z	Mark Saldanha	AHAPS0915M	Managing Director	Remuneration			0		
Total value of transaction during the reporting period											

Details of Impact of Audit Qualification			
Whether results are audited or unaudited		Unaudited	
Declaration of unmodified opinion or statement on impact of audit qualification		Declaration of unmodified opinion	
Auditor's opinion			
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results		Yes	
	Audit firm's name	Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI	Certificate valid upto
1	MSKA & Associates	Yes	31-07-2027

Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)	
Mode of Fund Raising	Preferential Issues
Description of mode of fund raising (Applicable in case of others is selected)	
Date of Raising Funds	18-01-2023
Amount Raised	3724
Report filed for Quarter ended	30-09-2025
Monitoring Agency	Not applicable
Monitoring Agency Name, if applicable	
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	
If Yes, Date of shareholder Approval	
Explanation for the Deviation / Variation	No deviation / variation
Comments of the Audit Committee after review	Satisfactory
Comments of the auditors, if any	No

Sr.	Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
1	Expansion Programme	No	3724	0	3670.17	0	

Signatory Details

Name of signatory	Harshavardhan Panigrahi
Designation of person	Company Secretary and Compliance Officer
Place	Mumbai
Date	12-11-2025

